Video
Dr. McDermott on Immunotherapy as a Standard of Care in RCC
Author(s):
David F. McDermott, MD, director of the Biologic Therapy Program at Beth Israel Deaconess Medical Center, discusses immunotherapy as a standard of care for patients with renal cell carcinoma (RCC).
David F. McDermott, MD, director of the Biologic Therapy Program at Beth Israel Deaconess Medical Center, discusses immunotherapy as a standard of care for patients with renal cell carcinoma (RCC).
According to McDermott, immunotherapy will be the standard of care for patients with RCC in 2018; however, it will not benefit everyone.
Patients with good-risk clinical features did very well with sunitinib (Sutent) in the CheckMate-214 trial, so there may be some patients who could benefit from single-agent VEGF inhibitors, explains McDermott.
Latest CME
View All
Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation
Jun 6th 2025 - Jul 12th 2025
Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC
Jun 6th 2025 - Jul 12th 2025
Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing
Jun 5th 2025 - Jul 12th 2025
